OZMOSI and Planview have partnered to link external scientific data with internal R&D planning to support pharmaceutical organisations.

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

UK Biobank data from all 500,000 participants within the charity’s health database was put up for sale on the Chinese e-commerce website Alibaba.

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical trials.

Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.

Sanofi has received approval from the US FDA for a supplemental biologic licence application for Tzield, allowing its use to delay stage 3 T1D onset in children as young as one year diagnosed with ...

This Durham-based facility will be AbbVie’s first manufacturing site in the state, and will become a centre of excellence for SVP production.

In global nephrology studies, aligning biology, design, operations, and interpretation across regions is essential for avoiding small missteps that could amplify through development.

MSD and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI enterprise transformation.

Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.

GlobalData analysts forecast a blockbuster future for Idvynso, though they note it is unlikely it will displace market dominator, Biktarvy.

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.